Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genmab A/S (GMAB)

36.445   0.19 (0.52%) 09-26 15:29
Open: 36.48 Pre. Close: 36.255
High: 36.71 Low: 36.4
Volume: 353,446 Market Cap: 23,803(M)

Technical analysis

as of: 2023-09-26 2:49:30 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 44.48     One year: 46.17
Support: Support1: 35.75    Support2: 29.75
Resistance: Resistance1: 38.08    Resistance2: 39.52
Pivot: 37.18
Moving Average: MA(5): 36.55     MA(20): 37.52
MA(100): 38.79     MA(250): 39.36
MACD: MACD(12,26): -0.4     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 15.1     %D(3): 14.1
RSI: RSI(14): 43
52-week: High: 47.5  Low: 31.39
Average Vol(K): 3-Month: 485 (K)  10-Days: 446 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GMAB ] has closed above bottom band by 26.6%. Bollinger Bands are 17.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 36.39 - 36.59 36.59 - 36.78
Low: 35.22 - 35.49 35.49 - 35.73
Close: 35.86 - 36.26 36.26 - 36.61

Company Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Headline News

Tue, 26 Sep 2023
Positive Outlook for Genmab with Moderate Buy Rating and 4630 ... - Best Stocks

Tue, 26 Sep 2023
Genmab Announces European Commission Approval of TEPKINLY ... - BioSpace

Mon, 25 Sep 2023
AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R ... - RTTNews

Mon, 25 Sep 2023
AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R ... - Nasdaq

Mon, 25 Sep 2023
Genmab A/S (GMAB) Announces EPKINLY Approved by Japan ... -

Mon, 25 Sep 2023
EPKINLYâ„¢ (epcoritamab) Approved by Japan Ministry of Health ... - Galveston County Daily News

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 653 (M)
Shares Float 645 (M)
% Held by Insiders 0 (%)
% Held by Institutions 6.6 (%)
Shares Short 2,890 (K)
Shares Short P.Month 4,190 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 44.04
Profit Margin (%) 29
Operating Margin (%) 40.1
Return on Assets (ttm) 13.8
Return on Equity (ttm) 17.8
Qtrly Rev. Growth 32.7
Gross Profit (p.s.) 22.35
Sales Per Share 25.06
EBITDA (p.s.) 10.61
Qtrly Earnings Growth -28.2
Operating Cash Flow 6,040 (M)
Levered Free Cash Flow 3,660 (M)

Stock Valuations

PE Ratio 36.17
PEG Ratio 0.1
Price to Book value 0.82
Price to Sales 1.45
Price to Cash Flow 3.95

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.